SERA icon

Sera Prognostics

2.68 USD
+0.04
1.52%
Updated Aug 26, 10:41 AM EDT
1 day
1.52%
5 days
19.64%
1 month
-14.65%
3 months
59.52%
6 months
-36.04%
Year to date
-67.83%
1 year
-63.59%
5 years
-77.48%
10 years
-77.48%
 

About: Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Employees: 64

0
Funds holding %
of 7,431 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,067% more call options, than puts

Call options by funds: $35K | Put options by funds: $3K

4.49% less ownership

Funds ownership: 55.13% [Q1] → 50.63% (-4.49%) [Q2]

18% less funds holding

Funds holding: 71 [Q1] → 58 (-13) [Q2]

31% less capital invested

Capital invested by funds: $74.4M [Q1] → $51.5M (-$23M) [Q2]

44% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 25

46% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 24

Research analyst outlook

We haven’t received any recent analyst ratings for SERA.

Financial journalist opinion

Based on 5 articles about SERA published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Austin Aerts - Chief Financial Officer Evguenia Lindgardt - President, CEO & Director Conference Call Participants Margarate Elizabeth Boeye - William Blair & Company L.L.C., Research Division William Ruby - TD Cowen, Research Division Peter DeNardo - Unidentified Company Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Second Quarter Fiscal Year 2025 Results.
Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Positive
The Motley Fool
2 weeks ago
Sera Prognostics (SERA) Q2 Loss Down 4%
Sera Prognostics (SERA 12.24%), a diagnostic company specializing in pregnancy risk prediction, reported Q2 2025 results on August 6, 2025. The company's headline news was a net loss improvement and continued strategic investment toward commercial rollout, despite revenue remaining extremely modest.
Sera Prognostics (SERA) Q2 Loss Down 4%
Negative
Zacks Investment Research
2 weeks ago
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.25 per share a year ago.
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Neutral
PRNewsWire
2 weeks ago
SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
SALT LAKE CITY , Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience.
SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Neutral
PRNewsWire
3 weeks ago
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025
SALT LAKE CITY , July 29, 2025 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025
Positive
Seeking Alpha
1 month ago
Sera Prognostics: PreTRM Labor Test Should Represent Advance In Risk Assessment
Sera Prognostics' PreTRM test shows strong clinical utility in reducing neonatal morbidity and NICU admissions, outperforming standard cervical length screening. The company is well-capitalized with $114 million in cash, sufficient to fund commercialization efforts into 2028, despite current losses. Key growth drivers include commercial reimbursement, Medicaid coverage, and inclusion in clinical guidelines, targeting a large and underserved preterm birth market.
Sera Prognostics: PreTRM Labor Test Should Represent Advance In Risk Assessment
Negative
Zacks Investment Research
2 months ago
After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)
Neutral
PRNewsWire
2 months ago
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
SALT LAKE CITY , May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference Date: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Officer, will participate in meetings on Wednesday, June 4, 2025.
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Neutral
PRNewsWire
3 months ago
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements.
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE
Positive
Zacks Investment Research
3 months ago
Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround
Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround
Charts implemented using Lightweight Charts™